Hepatitis C virus superinfection in hepatitis B virus chronic carriers: A reciprocal viral interaction and a variable clinical course

Change in Fibrosis Score as a Predictor of Mortality Among HIV-Infected Patients with Viral Hepatitis

“…Samples obtained prior to ART initiation showed that triply infected patients had a trend toward lower HBV DNA levels, similar to other reports in HBV/HCV patients. [22][23][24] No difference in HCV RNA levels in the triply infected patients was observed when compared to the HIV/ HCV coinfected group; this result differs from a recent study. 24 Hepatitis D virus infection occurred more often in those with triple infection, suggesting that the intravenous/parenteral route is the most likely mode of transmission of these infections.…”

Development of novel agents for the treatment of chronic hepatitis C infection: Summary of the FDA Antiviral Products Advisory Committee recommendations

“…The FDA convened a meeting of the Antiviral Products Advisory Committee on October [19][20]2006, to discuss specific issues related to development and approval of novel agents for the treatment of hepatitis C. Advisory committees provide the FDA with independent advice from outside experts on issues related to human and veterinary drugs, biological products, medical devices, and food. In general, advisory committees include a Chair, several members, plus a consumer, industry, and sometimes a patient representative.…”

“…Studies in HCV/ hepatitis B virus (HBV) coinfected patients were judged to represent a lower priority because of the low prevalence of this population and the observation that one viral type typically dominated the clinical picture in a given patient. 20,21 Pre-and Posttransplantation. Prior to liver transplantation for HCV-associated liver disease, there are two goals of therapy.…”

HBV superinfection in HCV chronic carriers: A disease that is frequently severe but associated with the eradication of HCV #

“…A marked inhibition of the preexisting viral replication has been observed both in HBV chronic carriers with superimposed acute hepatitis C 12-15 and in HCV chronic carriers with HBV superinfection, [16][17][18] both models being frequently characterized by a severe clinical course. 15,18 In a study on HBV superinfection in HCV chronic carriers, the inhibition exerted by HBV on the HCV genome persisted during a follow-up of 1 year in half of the patients, 18 but a comprehensive evaluation of the virus interaction and clinical outcome was hampered by the lack of information on HCV replication before HBV superinfection by the low sensitivity of the HBV-DNA assay used and the short follow-up period.The present article describes a case-control study performed on 29 HCV chronic carriers with HBV superinfection and 29 anti-HCV negative pair-matched controls who developed acute hepatitis B in the same period. Most of the patients with HBV superinfection had been observed for at least 1 year before the onset of acute hepatitis…”

“…10,11 Models of HBV and HCV superinfection have also been investigated. A marked inhibition of the preexisting viral replication has been observed both in HBV chronic carriers with superimposed acute hepatitis C [12][13][14][15] and in HCV chronic carriers with HBV superinfection, [16][17][18] both models being frequently characterized by a severe clinical course. 15,18 In a study on HBV superinfection in HCV chronic carriers, the inhibition exerted by HBV on the HCV genome persisted during a follow-up of 1 year in half of the patients, 18 but a comprehensive evaluation of the virus interaction and clinical outcome was hampered by the lack of information on HCV replication before HBV superinfection by the low sensitivity of the HBV-DNA assay used and the short follow-up period.…”